Then, to assess the efficacy of HIF2α-CD27 PAMs, we tested micelle binding to human patient tissue-derived ccRCC cells in vitro and evaluated their ability to inhibit cancer cell glucose transport, proliferation, release of angiogenic factors, and migration. Here, CD27 is linked to nonpapillary renal cell carcinoma.